Diabetic Neuropathy Market Expected to rise, 2034 | Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, expected to drive market

The Diabetic Neuropathy market growth is driven by factors like increase in the prevalence of Diabetic Neuropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Diabetic Neuropathy market report also offers comprehensive insights into the Diabetic Neuropathy market size, share, Diabetic Neuropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Diabetic Neuropathy market size growth forward.

Some of the key highlights from the Diabetic Neuropathy Market Insights Report:

Several key pharmaceutical companies, including Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, and others, are developing novel products to improve the Diabetic Neuropathy treatment outlook.
In November 2023, Lexicon Pharmaceuticals announced the enrollment of the first patient in PROGRESS, a Phase IIb, dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension, designed to evaluate LX9211 in patients with diabetic peripheral neuropathic pain.
Diabetic neuropathy is the most common microvascular complication in individuals with diabetes mellitus. After 20 years of disease progression, more than 50% of patients with diabetes are affected by this complication, significantly impacting their quality of life due to chronic pain in the lower limbs. According to the American Diabetes Association, chronic diabetic sensorimotor polyneuropathy (DSPN) is the most prevalent form, accounting for approximately 75% of all diabetic neuropathies.
In 2023, the United States had the highest number of diagnosed cases of diabetic neuropathy among the 7MM. Current treatments for diabetic neuropathic pain focus on addressing the underlying pathophysiological processes to prevent nerve damage, while symptomatic treatments aim to alleviate the painful symptoms and improve physical and psychological functioning. First-line therapies typically include tricyclic agents (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and γ-aminobutyric acid (GABA) analogs like gabapentin or pregabalin, followed by opioids and topical treatments.
Few therapies are currently being investigated for diabetic neuropathy, with companies like Helixmith, Pure Green, Vertex Pharmaceuticals, and Lexicon Pharmaceuticals leading the development efforts. In the United States, the majority of cases are of the peripheral type, representing about 60% of total cases.
In 2023, Germany had the highest number of diagnosed cases of diabetic neuropathy among the EU4 and the UK, while Spain reported the fewest cases. Emerging therapies, including LX9211, VX-548, Engenesis/VM202 (donaperminogene seltoplasmid), are expected to enter the market across the 7MM countries during the forecast period.
In the 7MM, the United States held the largest market share for diabetic neuropathy, accounting for approximately 80% of the market in 2023, followed by the UK, which had the largest share among the EU4 countries. Spain had the smallest market share. NSAIDs dominated the market in 2023, with NUCYNTA ER being the second-largest revenue generator.
The growth of the diabetic neuropathy market is expected to be driven by the aging population, increasing prevalence of diabetes, and advancements in healthcare technology. However, delays in diagnosis, severe complications, the economic burden, and a lack of understanding of the disease may hinder the market's progress.
As per DelveInsight analysis, the Diabetic Neuropathy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Diabetic Neuropathy Market Landscape https://www.delveinsight.com/report-store/diabetic-neuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Neuropathy Overview

Diabetic neuropathy is characterized by specific signs or symptoms indicating neuropathy in individuals with diabetes mellitus, once other potential causes of nerve damage have been ruled out. The most prevalent type of diabetic neuropathy is distal symmetric polyneuropathy (DSPN), which typically presents with a "stocking and glove" pattern, affecting the hands and lower limbs. Diabetes can also lead to other diffuse neuropathies, such as various autonomic neuropathies, including cardiac autonomic neuropathy, gastrointestinal dysmotility, and diabetic cystopathy or impotence. While less common, focal neuropathies can occur, affecting individual peripheral nerves, leading to isolated mononeuropathies or, in rarer cases, involving nerve roots, resulting in radiculopathy or polyradiculopathy.

Do you know the treatment paradigms for different countries? Download our Diabetic Neuropathy Market Sample Report https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Neuropathy Epidemiology Insights

In 2023, the Diabetic Neuropathy Market was valued at approximately USD 2,800 million, and it is projected to grow throughout the study period from 2020 to 2034 across the 7MM.
Among the 7MM countries, the United States had the largest market size for diabetic neuropathy in 2023, followed by Germany.

Diabetic Neuropathy Epidemiology Segmentation

DelveInsight's Diabetic Neuropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Diabetic Neuropathy historical patient pools and forecasted Diabetic Neuropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Diabetic Neuropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Diabetic Neuropathy Prevalence
Age-Specific Diabetic Neuropathy Prevalence
Gender-Specific Diabetic Neuropathy Prevalence
Diagnosed and Treatable Cases of Diabetic Neuropathy

Visit for more @ Diabetic Neuropathy Epidemiological Insights https://www.delveinsight.com/report-store/diabetic-neuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Neuropathy Treatment Market

Currently, there is no treatment that can reverse or consistently prevent the progression of diabetic neuropathy. Treatment strategies primarily aim at improving diabetes management and providing symptomatic relief. The initial step in managing the condition is glycemic control, which has been shown to reduce the frequency of falls and the occurrence of foot ulcers. The main approaches to treating peripheral neuropathy include glycemic control, foot care, and pain management. However, glycemic control alone has not been proven to significantly alleviate symptoms in peripheral neuropathy patients, so both glycemic control and foot care are mainly focused on prevention.
Diabetic Neuropathy Marketed Drugs
QUTENZA: Grünenthal and Averitas Pharma
Diabetic Neuropathy Emerging Drugs
ENGENSIS/VM202 (donaperminogene seltoplasmid): Helixmith
LX9211: Lexicon Pharmaceuticals
Diabetic Neuropathy Key Companies
Novo Nordisk
Ionis Pharmaceuticals
Pfizer
Regeneron
NeuroMetrix, and others
For more information, visit Diabetic Neuropathy Market Analysis, Patient Pool, and Emerging Therapies https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Diabetic Neuropathy Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Diabetic Neuropathy, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Diabetic Neuropathy epidemiology in the 7MM
Diabetic Neuropathy marketed and emerging therapies
Diabetic Neuropathy companies
Diabetic Neuropathy market drivers and barriers

Table of Contents:

1 Diabetic Neuropathy Market Key Comprehensive Insights
2 Diabetic Neuropathy Market Report Introduction
3 Competitive Intelligence Analysis for Diabetic Neuropathy
4 Diabetic Neuropathy Market Analysis Overview at a Glance
5 Executive Summary of Diabetic Neuropathy
6 Diabetic Neuropathy Epidemiology and Market Methodology
7 Diabetic Neuropathy Epidemiology and Patient Population
8 Diabetic Neuropathy Patient Journey
9 Diabetic Neuropathy Treatment Algorithm, Diabetic Neuropathy Current Treatment, and Medical Practices
10 Key Endpoints in Diabetic Neuropathy Clinical Trials
11 Diabetic Neuropathy Marketed Therapies
12 Diabetic Neuropathy Emerging Therapies
13 Diabetic Neuropathy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Diabetic Neuropathy
16 Diabetic Neuropathy Market Key Opinion Leaders Reviews
18 Diabetic Neuropathy Market Drivers
19 Diabetic Neuropathy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight

Related Reports:

Diabetic Neuropathy Epidemiology 2034

DelveInsight's "Diabetic Neuropathy - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Neuropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diabetic Neuropathy Pipeline 2024

"Diabetic Neuropathy Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diabetic Neuropathy market. A detailed picture of the Diabetic Neuropathy pipeline landscape is provided, which includes the disease overview and Diabetic Neuropathy treatment guidelines.

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.